You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNilvadipine
Accession NumberDB06712
TypeSmall Molecule
GroupsApproved
DescriptionNilvadipine is a calcium channel blocker (CCB) for treatment of hypertension.
Structure
Thumb
Synonyms
Nivadil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NivadilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0214FUT37J
CAS number75530-68-6
WeightAverage: 385.3707
Monoisotopic: 385.127385355
Chemical FormulaC19H19N3O6
InChI KeyInChIKey=FAIIFDPAEUKBEP-UHFFFAOYSA-N
InChI
InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
IUPAC Name
3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor the management of vasospastic angina, chronic stable angina and hypertension.
PharmacodynamicsNilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
Mechanism of actionNilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9377
Blood Brain Barrier-0.9749
Caco-2 permeable+0.6864
P-glycoprotein substrateSubstrate0.5516
P-glycoprotein inhibitor IInhibitor0.915
P-glycoprotein inhibitor IIInhibitor0.9125
Renal organic cation transporterNon-inhibitor0.9071
CYP450 2C9 substrateNon-substrate0.8306
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateSubstrate0.7268
CYP450 1A2 substrateInhibitor0.7753
CYP450 2C9 inhibitorInhibitor0.5318
CYP450 2D6 inhibitorNon-inhibitor0.9291
CYP450 2C19 inhibitorInhibitor0.6042
CYP450 3A4 inhibitorInhibitor0.6375
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8599
Ames testNon AMES toxic0.6114
CarcinogenicityNon-carcinogens0.5194
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.5335 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7842
hERG inhibition (predictor II)Non-inhibitor0.8944
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0124 mg/mLALOGPS
logP2.97ALOGPS
logP2.24ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)-0.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area134.24 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity101.8 m3·mol-1ChemAxon
Polarizability37.54 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Minoru Nakano, Toshinobu Uemura, Shinichi Morizane, Kiyoshi Okuda, Keiko Nakata, “Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine.” U.S. Patent US5340591, issued March, 1985.

US5340591
General ReferencesNot Available
External Links
ATC CodesC08CA10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nilvadipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nilvadipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nilvadipine.
AcebutololAcebutolol may increase the hypotensive activities of Nilvadipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nilvadipine.
AliskirenNilvadipine may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Nilvadipine.
AmbrisentanNilvadipine may increase the hypotensive activities of Ambrisentan.
AmifostineNilvadipine may increase the hypotensive activities of Amifostine.
AmiodaroneThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Nilvadipine.
AmobarbitalThe metabolism of Nilvadipine can be increased when combined with Amobarbital.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nilvadipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nilvadipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nilvadipine.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nilvadipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nilvadipine.
AprepitantThe serum concentration of Nilvadipine can be increased when it is combined with Aprepitant.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nilvadipine.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nilvadipine resulting in a loss in efficacy.
AtazanavirThe metabolism of Nilvadipine can be decreased when combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Nilvadipine.
AtomoxetineThe metabolism of Nilvadipine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Atosiban.
Atracurium besylateNilvadipine may increase the neuromuscular blocking activities of Atracurium besylate.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nilvadipine.
BarbitalThe metabolism of Nilvadipine can be increased when combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Nilvadipine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nilvadipine.
BenmoxinBenmoxin may increase the hypotensive activities of Nilvadipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nilvadipine.
BepridilBepridil may increase the hypotensive activities of Nilvadipine.
BetaxololBetaxolol may increase the hypotensive activities of Nilvadipine.
BethanidineBethanidine may increase the hypotensive activities of Nilvadipine.
BexaroteneThe serum concentration of Nilvadipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nilvadipine.
BimatoprostBimatoprost may increase the hypotensive activities of Nilvadipine.
BisoprololBisoprolol may increase the hypotensive activities of Nilvadipine.
BoceprevirThe metabolism of Nilvadipine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Nilvadipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nilvadipine can be decreased when it is combined with Bosentan.
BosentanNilvadipine may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the hypotensive activities of Nilvadipine.
BrimonidineNilvadipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nilvadipine.
BupranololNilvadipine may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nilvadipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nilvadipine.
CandesartanCandesartan may increase the hypotensive activities of Nilvadipine.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nilvadipine.
CandoxatrilCandoxatril may increase the hypotensive activities of Nilvadipine.
CaptoprilCaptopril may increase the hypotensive activities of Nilvadipine.
CarbamazepineThe metabolism of Nilvadipine can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nilvadipine.
CarteololCarteolol may increase the hypotensive activities of Nilvadipine.
CarvedilolCarvedilol may increase the hypotensive activities of Nilvadipine.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nilvadipine.
CeliprololCeliprolol may increase the hypotensive activities of Nilvadipine.
CeritinibThe serum concentration of Nilvadipine can be increased when it is combined with Ceritinib.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nilvadipine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nilvadipine.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nilvadipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nilvadipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nilvadipine.
CilazaprilCilazapril may increase the hypotensive activities of Nilvadipine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nilvadipine.
CimetidineThe serum concentration of Nilvadipine can be increased when it is combined with Cimetidine.
ClarithromycinThe metabolism of Nilvadipine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Nilvadipine can be decreased when combined with Clemastine.
ClonidineClonidine may increase the hypotensive activities of Nilvadipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine.
ClotrimazoleThe metabolism of Nilvadipine can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Nilvadipine can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Nilvadipine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Nilvadipine can be decreased when combined with Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Nilvadipine.
CyclosporineThe metabolism of Nilvadipine can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Nilvadipine.
Cyproterone acetateThe serum concentration of Nilvadipine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nilvadipine.
DarunavirThe metabolism of Nilvadipine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.
DebrisoquinDebrisoquin may increase the hypotensive activities of Nilvadipine.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nilvadipine.
DeferasiroxThe serum concentration of Nilvadipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nilvadipine can be decreased when combined with Delavirdine.
DeserpidineNilvadipine may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Nilvadipine can be decreased when it is combined with Dexamethasone.
DiazoxideDiazoxide may increase the hypotensive activities of Nilvadipine.
DihydroergotamineThe metabolism of Nilvadipine can be decreased when combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Nilvadipine.
DisulfiramThe metabolism of Nilvadipine can be decreased when combined with Disulfiram.
DorzolamideDorzolamide may increase the hypotensive activities of Nilvadipine.
DoxazosinDoxazosin may increase the hypotensive activities of Nilvadipine.
DoxycyclineThe metabolism of Nilvadipine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Nilvadipine can be decreased when combined with Dronedarone.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nilvadipine.
EfavirenzThe serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nilvadipine.
EfonidipineNilvadipine may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Nilvadipine.
EnalaprilatNilvadipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide.
EpoprostenolEpoprostenol may increase the hypotensive activities of Nilvadipine.
EprosartanEprosartan may increase the hypotensive activities of Nilvadipine.
ErythromycinThe metabolism of Nilvadipine can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Nilvadipine can be decreased when it is combined with Eslicarbazepine acetate.
EtravirineThe serum concentration of Nilvadipine can be decreased when it is combined with Etravirine.
FelodipineFelodipine may increase the hypotensive activities of Nilvadipine.
FenoldopamFenoldopam may increase the hypotensive activities of Nilvadipine.
FluconazoleThe serum concentration of Nilvadipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nilvadipine.
FluvoxamineThe metabolism of Nilvadipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Nilvadipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nilvadipine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Nilvadipine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nilvadipine.
FosphenytoinThe metabolism of Nilvadipine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Nilvadipine.
Fusidic AcidThe serum concentration of Nilvadipine can be increased when it is combined with Fusidic Acid.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nilvadipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nilvadipine.
GuanabenzGuanabenz may increase the hypotensive activities of Nilvadipine.
GuanadrelGuanadrel may increase the hypotensive activities of Nilvadipine.
GuanethidineGuanethidine may increase the hypotensive activities of Nilvadipine.
GuanfacineGuanfacine may increase the hypotensive activities of Nilvadipine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nilvadipine.
HexamethoniumNilvadipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nilvadipine.
HexobarbitalThe metabolism of Nilvadipine can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nilvadipine.
HydralazineHydralazine may increase the hypotensive activities of Nilvadipine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nilvadipine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nilvadipine.
IdelalisibThe serum concentration of Nilvadipine can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Nilvadipine.
ImatinibThe metabolism of Nilvadipine can be decreased when combined with Imatinib.
IndapamideIndapamide may increase the hypotensive activities of Nilvadipine.
IndenololNilvadipine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Nilvadipine can be decreased when combined with Indinavir.
IndoraminNilvadipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Nilvadipine.
IproniazidIproniazid may increase the hypotensive activities of Nilvadipine.
IrbesartanIrbesartan may increase the hypotensive activities of Nilvadipine.
IsavuconazoniumThe metabolism of Nilvadipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nilvadipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nilvadipine.
IsoniazidThe metabolism of Nilvadipine can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the hypotensive activities of Nilvadipine.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nilvadipine.
IvacaftorThe serum concentration of Nilvadipine can be increased when it is combined with Ivacaftor.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Nilvadipine.
LabetalolLabetalol may increase the hypotensive activities of Nilvadipine.
LacidipineNilvadipine may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Nilvadipine.
LercanidipineLercanidipine may increase the hypotensive activities of Nilvadipine.
LisinoprilLisinopril may increase the hypotensive activities of Nilvadipine.
LofexidineLofexidine may increase the hypotensive activities of Nilvadipine.
LopinavirThe metabolism of Nilvadipine can be decreased when combined with Lopinavir.
LosartanLosartan may increase the hypotensive activities of Nilvadipine.
LovastatinThe metabolism of Nilvadipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nilvadipine can be increased when it is combined with Luliconazole.
MacitentanNilvadipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium Sulfate.
ManidipineNilvadipine may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Nilvadipine.
MecamylamineMecamylamine may increase the hypotensive activities of Nilvadipine.
MethohexitalThe metabolism of Nilvadipine can be increased when combined with Methohexital.
MethyldopaMethyldopa may increase the hypotensive activities of Nilvadipine.
Methylene blueMethylene blue may increase the hypotensive activities of Nilvadipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nilvadipine.
MethylphenobarbitalThe metabolism of Nilvadipine can be increased when combined with Methylphenobarbital.
MetipranololMetipranolol may increase the hypotensive activities of Nilvadipine.
MetolazoneMetolazone may increase the hypotensive activities of Nilvadipine.
MetoprololMetoprolol may increase the hypotensive activities of Nilvadipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nilvadipine.
MibefradilMibefradil may increase the hypotensive activities of Nilvadipine.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nilvadipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nilvadipine.
MifepristoneThe metabolism of Nilvadipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nilvadipine.
MinaprineMinaprine may increase the hypotensive activities of Nilvadipine.
MinoxidilMinoxidil may increase the hypotensive activities of Nilvadipine.
MitotaneThe serum concentration of Nilvadipine can be decreased when it is combined with Mitotane.
MivacuriumNilvadipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Nilvadipine.
ModafinilThe serum concentration of Nilvadipine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Nilvadipine.
MolsidomineMolsidomine may increase the hypotensive activities of Nilvadipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nilvadipine.
MoxonidineNilvadipine may increase the hypotensive activities of Moxonidine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nilvadipine.
NadololNadolol may increase the hypotensive activities of Nilvadipine.
NafcillinThe serum concentration of Nilvadipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nilvadipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nilvadipine.
NebivololNebivolol may increase the hypotensive activities of Nilvadipine.
NefazodoneThe metabolism of Nilvadipine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Nilvadipine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Nilvadipine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Nilvadipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Nilvadipine.
NicardipineNicardipine may increase the hypotensive activities of Nilvadipine.
NicorandilNilvadipine may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nilvadipine can be decreased when combined with Nicotine.
NiguldipineNilvadipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Nilvadipine can be decreased when combined with Nilotinib.
NimodipineNimodipine may increase the hypotensive activities of Nilvadipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nilvadipine.
NisoldipineNisoldipine may increase the hypotensive activities of Nilvadipine.
NitrendipineNitrendipine may increase the hypotensive activities of Nilvadipine.
NitroprussideNilvadipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nilvadipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nilvadipine.
ObinutuzumabNilvadipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nilvadipine.
OlaparibThe metabolism of Nilvadipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Nilvadipine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Nilvadipine.
OsimertinibThe serum concentration of Nilvadipine can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nilvadipine.
OxprenololOxprenolol may increase the hypotensive activities of Nilvadipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nilvadipine.
PalbociclibThe serum concentration of Nilvadipine can be increased when it is combined with Palbociclib.
PargylinePargyline may increase the hypotensive activities of Nilvadipine.
PenbutololPenbutolol may increase the hypotensive activities of Nilvadipine.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nilvadipine.
PentobarbitalThe metabolism of Nilvadipine can be increased when combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Nilvadipine.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nilvadipine.
PerindoprilPerindopril may increase the hypotensive activities of Nilvadipine.
PhenelzinePhenelzine may increase the hypotensive activities of Nilvadipine.
PheniprazinePheniprazine may increase the hypotensive activities of Nilvadipine.
PhenobarbitalThe metabolism of Nilvadipine can be increased when combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nilvadipine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nilvadipine.
PhentolaminePhentolamine may increase the hypotensive activities of Nilvadipine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nilvadipine.
PhenytoinThe metabolism of Nilvadipine can be increased when combined with Phenytoin.
PinacidilNilvadipine may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Nilvadipine.
PirlindolePirlindole may increase the hypotensive activities of Nilvadipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nilvadipine.
PolythiazidePolythiazide may increase the hypotensive activities of Nilvadipine.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nilvadipine.
PrazosinPrazosin may increase the hypotensive activities of Nilvadipine.
PrimidoneThe metabolism of Nilvadipine can be increased when combined with Primidone.
PropranololPropranolol may increase the hypotensive activities of Nilvadipine.
QuinaprilQuinapril may increase the hypotensive activities of Nilvadipine.
QuinineQuinine may increase the hypotensive activities of Nilvadipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nilvadipine.
RamiprilRamipril may increase the hypotensive activities of Nilvadipine.
RanolazineThe metabolism of Nilvadipine can be decreased when combined with Ranolazine.
RapacuroniumNilvadipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Nilvadipine.
RemikirenRemikiren may increase the hypotensive activities of Nilvadipine.
RescinnamineNilvadipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nilvadipine.
RifabutinThe metabolism of Nilvadipine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Nilvadipine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Nilvadipine can be increased when combined with Rifapentine.
RiociguatNilvadipine may increase the hypotensive activities of Riociguat.
RitonavirThe metabolism of Nilvadipine can be decreased when combined with Ritonavir.
RituximabNilvadipine may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Nilvadipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nilvadipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nilvadipine.
SaprisartanSaprisartan may increase the hypotensive activities of Nilvadipine.
SaquinavirThe metabolism of Nilvadipine can be decreased when combined with Saquinavir.
SecobarbitalThe metabolism of Nilvadipine can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Nilvadipine.
SelexipagNilvadipine may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nilvadipine.
SildenafilSildenafil may increase the antihypertensive activities of Nilvadipine.
SilodosinSilodosin may increase the hypotensive activities of Nilvadipine.
SiltuximabThe serum concentration of Nilvadipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nilvadipine can be increased when it is combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nilvadipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nilvadipine.
SitaxentanNilvadipine may increase the hypotensive activities of Sitaxentan.
SpiraprilSpirapril may increase the hypotensive activities of Nilvadipine.
St. John's WortThe serum concentration of Nilvadipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nilvadipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nilvadipine.
SulfisoxazoleThe metabolism of Nilvadipine can be decreased when combined with Sulfisoxazole.
TadalafilTadalafil may increase the antihypertensive activities of Nilvadipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nilvadipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nilvadipine.
TelaprevirThe metabolism of Nilvadipine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Nilvadipine can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Nilvadipine.
TemocaprilNilvadipine may increase the hypotensive activities of Temocapril.
TerazosinTerazosin may increase the hypotensive activities of Nilvadipine.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nilvadipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nilvadipine.
TerlipressinTerlipressin may increase the hypotensive activities of Nilvadipine.
ThiamylalThe metabolism of Nilvadipine can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Nilvadipine can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nilvadipine.
TiboloneNilvadipine may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Nilvadipine can be decreased when combined with Ticlopidine.
TicrynafenTicrynafen may increase the hypotensive activities of Nilvadipine.
TimololTimolol may increase the hypotensive activities of Nilvadipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nilvadipine.
TocilizumabThe serum concentration of Nilvadipine can be decreased when it is combined with Tocilizumab.
TolazolineTolazoline may increase the hypotensive activities of Nilvadipine.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nilvadipine.
ToloxatoneToloxatone may increase the hypotensive activities of Nilvadipine.
TorasemideTorasemide may increase the hypotensive activities of Nilvadipine.
TrandolaprilTrandolapril may increase the hypotensive activities of Nilvadipine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nilvadipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nilvadipine.
TravoprostTravoprost may increase the hypotensive activities of Nilvadipine.
TreprostinilTreprostinil may increase the hypotensive activities of Nilvadipine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nilvadipine.
TrimazosinNilvadipine may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Nilvadipine.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nilvadipine.
UdenafilUdenafil may increase the antihypertensive activities of Nilvadipine.
UnoprostoneNilvadipine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Nilvadipine.
VardenafilVardenafil may increase the antihypertensive activities of Nilvadipine.
VenlafaxineThe metabolism of Nilvadipine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Nilvadipine can be decreased when combined with Verapamil.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nilvadipine.
XylometazolineXylometazoline may increase the hypotensive activities of Nilvadipine.
YohimbineYohimbine may decrease the antihypertensive activities of Nilvadipine.
ZiprasidoneThe metabolism of Nilvadipine can be decreased when combined with Ziprasidone.
Food Interactions
  • Take without regard to meals

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Rosenthal J: Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107. [PubMed:7898101 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16. [PubMed:16484345 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8. [PubMed:20933604 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Rosenthal J: Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107. [PubMed:7898101 ]
  2. Honerjager P, Seibel K: Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. J Cardiovasc Pharmacol. 1992;20 Suppl 6:S15-21. [PubMed:1283184 ]
  3. Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8. [PubMed:20933604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated ion channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).
Gene Name:
CACNA2D3
Uniprot ID:
Q8IZS8
Molecular Weight:
123010.22 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194 ]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839 ]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509 ]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on May 16, 2010 11:33 / Updated on August 17, 2016 12:24